StarkAge Therapeutics: a unique and relentless focus on senescence

Filter by

juillet 7, 2025

Estimated reading time : 1 min.

Articles

Dipeptidyl Peptidase 4 (DPP4) as a new convincing target to eliminate cancer and senescent cancer cells

Read the article

Estimated reading time : 1 min.

Articles

Dipeptidyl peptidase 4 (DPP4) as a new senescence-associated target to eliminate cancer cells

Read the article

novembre 27, 2024

Estimated reading time : 1 min.

Articles

NewsLetter #6

Read the article

mai 27, 2024

Estimated reading time : 1 min.

Articles

StarkAge Therapeutics at AACR 2024 (San Diego)

Read the article

octobre 9, 2022

Estimated reading time : 1 min.

Articles

StarkAge Therapeutics present their most recent findings at ICSA 2022

Read the article

août 23, 2022

Estimated reading time : 2 mins.

Articles

Identification of senescent cell surface markers as immunotherapeutic targets

Read the article

StarkAge Therapeutics Awarded Winner of the 2024 I-Nov Innovation Competition Organized by Bpifrance

Juin 19, 2025

Read the document

Appointment of Dr. Benjamin LeCalvé as Chief Executive Officer (CEO) of StarkAge Therapeutics

Nov 26, 2024

Read the document

StarkAge Therapeutics raises €1.2m to accelerate the development of STX-1

Mai 29, 2024

Read the document

Starkage Therapeutics appoints Benjamin Le Calvé as CSO

Mai 10, 2022

Read the document

StarkAge Therapeutics establishes its Scientific Advisor Board of international independent experts and has their foundational meeting

Fév 13, 2022

Read the document

StarkAge Therapeutics awarded €2m from BPI France to develop innovative immunotherapy approach targeting senescent cells in age-related diseases

Jan 18, 2022

Read the document

Filter by

Want to receive news from StarkAge Therapeutics ?

Click here to be updated on news from StarkAge Therapeutics